Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
QHSLab, Inc. (USAQ)
West Palm Beach, FL, US
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops digital therapeutic solutions and on-site technologies intended for remote patient oversight, the management of chronic conditions, and proactive health maintenance. Among its offerings is a proprietary cloud-based SaaS platform, also known as QHSLab (Quality Health Score Lab expert system). This system empowers physicians and healthcare organizations to securely record and store electronic patient data. Additionally, QHSLab, Inc. acts as a distributor, providing primary care physicians with AllergiEnd, a product line encompassing diagnostic tools and allergen immunotherapy treatments. All of its solutions are strategically designed to aid in the prevention, early identification, effective management, and potential reversal of chronic diseases. The company was established in 1983 and is headquartered in West Palm Beach, Florida. It operated under the name USA Equities Corp. until April 2022, when it officially rebranded to QHSLab, Inc. The company also maintains a strategic partnership with Medical License Factory, LLC.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -18.18% | -18.18% | -28.90% | -37.86% | +174.39% | -25.73% | +164.71% | +400.00% | -28.57% | +309.09% | +80.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+26.3% ★ Q1'26: +12.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+179.4% ★ Q1'26: +2.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+26.5% ★ Q1'26: -27.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+25.8% ★ Q1'26: +0.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+68.9% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+88.0% Q1'26: +34.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.03× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
124.5K
est: 120.0K (+3.8%)
|
1.41M
est: 1.48M (-4.7%)
|
1.24M
est: 1.28M (-2.5%)
|
1.41M
est: 3.00M (-53.0%)
|
2.13M
est: 2.13M (+0.0%)
|
2.69M
est: 2.69M (+0.0%)
|
3.22M
3.22M – 3.22M
+19.7% YoY
|
3.86M
3.86M – 3.86M
+19.7% YoY
|
| EBITDA |
-296.4K
est: -38.3K (-674.9%)
|
-487.6K
est: -473.1K (-3.1%)
|
-434.6K
est: -406.4K (-6.9%)
|
-91.3K
est: -956.3K (+90.5%)
|
352.4K
est: -679.6K (+151.9%)
|
785.6K
est: -162.6K (+583.2%)
|
-194.6K
-194.6K – -194.6K
-19.7% YoY
|
-232.9K
-232.9K – -232.9K
-19.7% YoY
|
| EBIT |
-296.4K
est: -45.5K (-551.7%)
|
-523.7K
est: -562.4K (+6.9%)
|
-562.6K
est: -483.2K (-16.4%)
|
-237.9K
est: -1.14M (+79.1%)
|
205.8K
est: -808.0K (+125.5%)
|
694.8K
est: -342.9K (+302.6%)
|
-410.4K
-410.4K – -410.4K
-19.7% YoY
|
-491.3K
-491.3K – -491.3K
-19.7% YoY
|
| Net Income |
-327.4K
est: -514.4K (+36.4%)
|
-770.2K
est: -926.0K (+16.8%)
|
-996.0K
est: -1.23M (+19.3%)
|
-468.4K
est: -411.5K (-13.8%)
|
-259.2K
est: 514.4K (-150.4%)
|
457.4K
est: 3.87M (-88.2%)
|
5.80M
5.80M – 5.80M
+50.0% YoY
|
7.35M
7.35M – 7.35M
+26.7% YoY
|
| SGA |
226.9K
est: 100.8K (+125.2%)
|
1.05M
est: 1.25M (-16.1%)
|
917.8K
est: 1.07M (-14.3%)
|
747.6K
est: 2.52M (-70.3%)
|
785.6K
est: 1.79M (-56.1%)
|
1.12M
est: 1.50M (-25.4%)
|
1.80M
1.80M – 1.80M
+19.7% YoY
|
2.16M
2.16M – 2.16M
+19.7% YoY
|
| EPS |
-0.05
est: -0.05 (-5.6%)
|
-0.10
est: -0.09 (-8.9%)
|
-0.11
est: -0.12 (+8.3%)
|
-0.05
est: -0.04 (-24.3%)
|
-0.03
est: 0.05 (-150.4%)
|
0.04
est: 0.20 (-80.0%)
|
0.30
0.30 – 0.30
+50.0% YoY
|
0.38
0.38 – 0.38
+26.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALFRED J. ROACH | 3.05M | 16.20% | 3.05M | — | 3.05M | — | IN | United States of America | 1997-02-24 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-29 | Marvin Smollar Family Trust dtd 2/13/2023 | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 2,226,280 | I | ↗ |
| 2021-12-31 | Grogan Troy James | Director / Officer / 10% Owner | J-Other | A | Series A-2 Convertible Preferred Stock | 2,644,424 | 0.16 | 423.1K | 2,644,424 | D | ↗ |
| 2020-09-30 | Grogan Troy James | Director / Officer / 10% Owner | — | D | Convertible Note $88,016 | 88,016 | 1.00 | 88.0K | 0 | — | ↗ |
| 2020-02-27 | Grogan Troy James | Director / Officer / 10% Owner | J-Other | A | Convertible Promissory Note | 1 | 0.10 | 0.10 | 3 | — | ↗ |
| 2020-02-20 | Grogan Troy James | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,270,000 | — | ↗ |
| 2019-12-27 | Grogan Troy James | Director / Officer / 10% Owner | — | D | Convertible Note $88,626 | 161,138 | 0.55 | 88.6K | 0 | — | ↗ |
| 2019-09-01 | Grogan Troy James | Director / Officer / 10% Owner | — | D | Series A Preferred Stock | 5,400,460 | 0.05 | 270.0K | 0 | — | ↗ |
| 2019-08-05 | Grogan Troy James | Director / Officer / 10% Owner | — | D | Convertible Note $124,562 | 500,000 | 0.25 | 125.0K | 0 | — | ↗ |
| 2009-10-09 | Grogan Troy James | Director / Officer / 10% Owner | — | D | Convertible Note $76,000 | 76,000,000 | 0.00 | 76.0K | 0 | — | ↗ |
| 2008-12-31 | RUBIN RICHARD J | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 152,000,000 | — | ↗ |
| 2007-12-31 | RUBIN RICHARD J | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-12-22 | RUBIN RICHARD J | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 122,000,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cyndi Cole | Financial Controller | — | female |
| Olivia Giamanco | Marketing Director | — | female |
| Troy James Grogan | Chief Executive Officer, Chief Financial Officer, President & Chairman | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for USAQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
